infecti
diseas
caus
virus
challeng
problem
human
health
diseas
high
infect
mortal
particularli
fear
past
peopl
regard
diseas
disast
punish
howev
improv
identifi
etiolog
viral
infect
knowledg
microbiolog
follow
develop
variou
vaccin
enabl
humankind
overcom
irrat
fear
death
invent
vaccin
regard
one
biggest
triumph
histori
medicin
vaccin
save
million
live
import
still
grow
although
numer
effort
focus
produc
qualifi
effect
vaccin
insuffici
barrier
protect
popul
diseas
may
caus
epidem
pandem
eg
ebola
viru
epidem
thu
research
tri
increas
number
diseas
prevent
vaccin
expand
target
popul
receiv
benefit
vaccin
futur
addit
vaccin
develop
strategi
tailor
particular
econom
health
requir
specif
countri
product
develop
number
type
clinic
trial
influenc
directli
trend
physician
other
involv
vaccin
develop
alert
current
paradigm
review
articl
briefli
summar
past
present
trend
clinic
vaccin
develop
aim
increas
understand
vaccin
develop
provid
uptod
inform
histori
develop
applic
vaccinelik
substanc
human
startedin
ancient
time
hilleman
depict
histori
concis
diagram
fig
accord
diagrammat
outlin
live
modern
era
vaccin
develop
success
product
period
histori
progress
depend
abund
financi
support
receiv
left
column
use
knowledg
base
experi
observ
peopl
centuri
practic
variol
first
known
method
human
immun
powder
scab
fluid
pustul
smallpox
patient
insert
superfici
scratch
made
skin
recipi
mani
variat
techniqu
use
china
middl
east
africa
spread
wide
throughout
europ
centuri
first
scientif
investig
techniqu
made
edward
jenner
use
cowpox
viru
rather
smallpox
scab
human
experi
base
doctrin
enlighten
origin
term
vaccin
begin
vaccinolog
despit
histor
achiev
jenner
insuffici
fundament
knowledg
microbiolog
new
vaccin
develop
centuri
late
centuri
heroic
scientist
loui
pasteur
robert
koch
emil
von
behr
paul
ehrlich
discov
basic
principl
develop
experiment
methodolog
immunolog
immunotherapi
led
next
stage
vaccinolog
follow
semin
investig
mani
studi
perform
led
improv
regul
eg
biolog
control
act
result
develop
valid
live
andor
attenu
vaccin
new
vaccin
diseas
includ
rabi
typhoid
fever
diphtheria
shigellosi
tuberculosi
tetanu
pertussi
develop
howev
period
vaccin
research
limit
area
public
andor
militari
need
world
war
restrict
fund
resourc
import
transit
vaccin
mass
product
began
good
pastur
find
viral
growth
embryon
hen
egg
variou
manufactur
techniqu
develop
basi
addit
number
largescal
human
test
improv
scientif
valid
increas
period
methodolog
random
blind
use
control
group
help
increas
accuraci
evalu
safeti
effect
vaccin
especi
world
war
ii
militari
purpos
remain
power
motiv
vaccin
develop
support
bodi
includ
public
agenc
foundat
eg
world
health
organ
rockefel
institut
arisen
sinc
vaccin
adenoviru
polioviru
japanes
b
enceph
viru
influenza
viru
develop
stage
second
half
centuri
defin
hilleman
modern
era
scientif
improv
relat
screen
manufactur
vaccin
product
enabl
develop
new
type
vaccin
plotkin
plotkin
regard
period
golden
age
vaccin
develop
age
began
develop
three
classic
attenuatedviru
vaccin
measl
mump
rubella
mmr
follow
varicella
zoster
viru
vaccin
inactiv
japanes
enceph
viru
vaccin
vaccin
involv
cell
cultur
techniqu
control
condit
certain
purpos
ie
attenu
manufactur
process
inactiv
whole
hepat
viru
cell
culturederiv
rabi
virus
also
develop
vaccin
product
use
similar
methodolog
conjug
bacteri
capsular
polysaccharid
protein
appli
realworld
set
although
propos
averi
goebel
thank
technolog
bacteri
vaccin
haemophilu
influenza
type
b
meningococcu
pneumococcu
introduc
multival
vaccin
variou
bacteri
serotyp
also
develop
develop
recombin
viral
vaccin
use
genet
engin
anoth
import
step
evolut
vaccinolog
first
exampl
type
vaccin
vaccin
hepat
b
viru
human
papillomaviru
vaccin
anoth
import
exampl
kind
vaccin
brought
dramat
improv
vaccin
safeti
mitig
risk
use
purifi
inactiv
antigen
obtain
infect
patient
meet
societi
need
safe
efficaci
vaccin
clinic
vaccin
develop
process
refin
centuri
similar
chemic
drug
clinic
evalu
vaccin
typic
compris
three
phase
fig
entir
process
take
year
requir
budget
billion
us
dollar
vaccinespecif
development
plan
clearli
establish
ensur
effici
success
develop
clinic
evalu
includ
follow
content
identif
target
popul
mostli
healthi
peopl
particular
demograph
characterist
sociocultur
factor
risk
assess
target
diseas
vaccin
understand
incid
target
diseas
environment
factor
identif
dose
rout
administr
plan
induc
herd
immun
regulatori
strategi
gener
characterist
clinic
vaccin
develop
compar
convent
drug
develop
summar
tabl
human
studi
accept
safeti
reactogen
vaccin
candid
achiev
phase
clinic
trial
phase
safeti
toler
evalu
local
system
level
primari
endpoint
doserang
andor
repeateddos
studi
often
perform
preliminari
inform
immunogen
efficaci
may
collect
trial
often
design
random
doubleblind
placebocontrol
singlecent
studi
accord
characterist
product
either
crossov
parallel
design
may
chosen
statist
analysi
gener
descript
exploratori
natur
trial
involv
small
number
particip
thu
suffici
inform
need
confirmatori
test
obtain
firstinhuman
set
attent
given
live
attenu
vaccin
risk
tend
higher
kill
vaccin
phase
ii
proofofconcept
poc
vaccin
product
ensur
clinic
trial
phase
conduct
demonstr
immunogen
relev
activ
compon
safeti
profil
candid
vaccin
within
target
popul
defin
optim
dose
initi
schedul
safeti
profil
candid
vaccin
these
purpos
often
achiev
separ
clinic
trial
phase
iia
phase
iib
design
clinic
trial
multipl
variabl
associ
host
immun
respons
consid
determin
clinic
applic
vaccin
regimen
also
includ
dose
number
dose
sequenceinterv
dose
rout
administr
vaccin
efficaci
may
evalu
use
welldefin
surrog
paramet
clinic
trial
includ
parallel
group
comparison
placeboact
control
group
prospect
confirmatori
statist
analys
perform
percentag
respond
defin
describ
base
predefin
criteria
immun
respons
eg
antibodi
andor
cellmedi
immun
final
step
clinic
evalu
product
licens
phase
iii
trial
stage
intend
provid
pivot
conclus
need
market
approv
efficaci
safeti
formul
immunolog
activ
compon
must
assess
largescal
target
popul
clinic
outcom
strongli
recommend
paramet
compar
efficaci
eg
placeboact
control
group
therefor
serolog
data
usual
collect
least
subset
immun
popul
predefin
interv
design
phase
ii
phase
iii
clinic
trial
similar
size
phase
iii
trial
much
larger
consider
modern
vaccin
strategyadministr
multipl
vaccin
timeinteract
andor
interfer
vaccin
evalu
routin
sometim
possibl
conduct
confirmatori
studi
determin
protect
efficaci
product
contain
antigen
alreadi
use
commonli
andor
whose
target
diseas
low
incid
inform
obtain
development
process
mention
summar
file
submiss
regulatori
author
support
applic
market
approv
regulatori
author
guidelin
ensur
qualiti
inform
provid
exampl
unit
state
food
drug
administr
fda
call
process
biolog
licens
applic
bla
multidisciplinari
fda
review
team
review
efficaci
safeti
inform
need
make
riskbenefit
assess
advis
vaccin
relat
biolog
product
advisori
committe
vrbpac
appropri
label
content
reliabl
manufactur
process
also
review
even
though
vaccin
may
licens
safeti
inform
provid
licensur
regard
insuffici
point
thousand
peopl
like
expos
vaccin
thu
mani
vaccin
undergo
postlicensur
phase
iv
studi
unit
state
vaccin
advers
event
report
system
vaer
establish
detect
possibl
signal
advers
event
associ
vaccin
one
import
aspect
vaccinolog
centuri
extens
target
popul
develop
new
vaccin
emerg
infect
tumor
chronic
diseas
ultim
goal
modern
vaccin
may
express
prevent
cure
mani
diseas
vaccin
possibl
rappuoli
et
al
present
concept
simpl
figur
fig
meet
challeng
requir
increas
number
vaccin
clinic
trial
nontradit
popul
worldwid
scientif
expertis
necessari
success
develop
new
vaccin
mani
initi
launch
recent
includ
decad
vaccin
millennium
develop
goal
us
institut
medicin
consensu
studi
identifi
priorit
new
prevent
vaccin
develop
anoth
focu
improv
efficaci
safeti
vaccin
even
beyond
overwhelm
success
vaccin
past
sever
centuri
import
keyword
efficaci
viewpoint
adjuv
number
vaccin
product
licens
develop
form
mixtur
vaccin
certain
adjuv
tabl
current
licens
adjuv
vaccin
product
target
influenza
emphasi
import
adjuv
gradual
increas
age
popul
facilit
immun
respons
vaccin
older
peopl
mani
expert
expect
adjuv
essenti
compon
widespread
vaccin
use
entir
popul
tradit
paradigm
diseas
caus
vaccin
seriou
problem
rappuoli
stress
methodolog
approach
use
overcom
risk
vaccin
centuri
tabl
addit
thank
improv
genom
techniqu
new
vaccinedesign
method
revers
vaccinolog
enabl
highthroughput
screen
vaccin
candid
greater
confid
safeti
profil
characterist
vaccin
recipi
also
consid
much
focu
develop
way
person
vaccin
term
vaccinom
without
doubt
quantiti
qualiti
clinic
vaccin
develop
improv
greatli
futur
simultan
coverag
vaccin
divers
diseas
broaden
faster
ever
integr
knowledg
microbiolog
immunolog
establish
effici
vaccin
develop
strategi
streamlin
regulatori
approv
process
may
facilit
trend
increas
chanc
human
societi
experi
continu
benefit
vaccin
